Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who have at least one of the hemorrhagic tendencies of following conditions and needs CRRT hemodynamically;~  1. Platelet count \< 100,000~ 2. aPTT \> 60 sec~ 3. PT-INR \> 2.0~ 4. active hemorrhage~ 5. surgery within 48 hours~ 6. cerebral hemorrhage within 3 months or history of major bleeding~ 7. septic shock or DIC.~Exclusion Criteria:~* pregnancy, breast feeding, possibility of pregnancy,~* allergy to nafamostat mesilate,~* other conditions that physician consider unfit for candidate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- M100 (Type: ACTIVE_COMPARATOR): heparin free CRRT group
- HF1000 (Type: EXPERIMENTAL): CRRT with nafamostat mesilate anticoagulation group

Based on this trial design, predict the completion outcome and termination type (if applicable).